Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew A Cavender

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
JACC. Cardiovascular Interventions|February 5, 2021
Acute Kidney Injury Following In-Patient Lower Extremity Vascular Intervention: From the National Cardiovascular Data RegistryDavid M Safley, Adam C Salisbury, Thomas T Tsai, et al.
Clinical Cardiology|October 3, 2013
Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: findings from Get With the Guidelines-Coronary Artery DiseaseMatthew A Cavender, Andrew N Rassi, Gregg C Fonarow, et al.
The American Journal of Cardiology|September 18, 2018
Meta-Analysis Comparing Complete or Culprit Only Revascularization in Patients With Multivessel Disease Presenting With Cardiogenic ShockMaurizio Bertaina, Ilenia Ferraro, Pierlugi Omedè, et al.
JAMA Network Open|April 24, 2023
Patients and Their Physician's Perspectives About Oral Anticoagulation in Patients With Atrial Fibrillation Not Receiving an AnticoagulantChristopher P Cannon, Joseph M Kim, Jane J Lee, et al.
Circulation. Cardiovascular Interventions|August 13, 2017
Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIXMatthew A Cavender, Deepak L Bhatt, Gregg W Stone, et al.
Circulation|August 3, 2016
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)Matthew A Cavender, Deepak L Bhatt, Gregg W Stone, et al.
JAMA|November 20, 2013
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trialStephen J Nicholls, John J P Kastelein, Gregory G Schwartz, et al.
Circulation. Cardiovascular Interventions|December 17, 2021
Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIXMatthew A Cavender, Robert A Harrington, Gregg W Stone, et al.
Journal of the American College of Cardiology|May 6, 2021
Predicting In-Hospital Mortality in Patients Undergoing Percutaneous Coronary InterventionYulanka S Castro-Dominguez, Yongfei Wang, Karl E Minges, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 30, 2020
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney FoundationKatherine R Tuttle, Frank C Brosius, Matthew A Cavender, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
JACC. Cardiovascular Interventions|February 5, 2021
Acute Kidney Injury Following In-Patient Lower Extremity Vascular Intervention: From the National Cardiovascular Data RegistryDavid M Safley, Adam C Salisbury, Thomas T Tsai, et al.
Clinical Cardiology|October 3, 2013
Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: findings from Get With the Guidelines-Coronary Artery DiseaseMatthew A Cavender, Andrew N Rassi, Gregg C Fonarow, et al.
The American Journal of Cardiology|September 18, 2018
Meta-Analysis Comparing Complete or Culprit Only Revascularization in Patients With Multivessel Disease Presenting With Cardiogenic ShockMaurizio Bertaina, Ilenia Ferraro, Pierlugi Omedè, et al.
JAMA Network Open|April 24, 2023
Patients and Their Physician's Perspectives About Oral Anticoagulation in Patients With Atrial Fibrillation Not Receiving an AnticoagulantChristopher P Cannon, Joseph M Kim, Jane J Lee, et al.
Circulation. Cardiovascular Interventions|August 13, 2017
Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIXMatthew A Cavender, Deepak L Bhatt, Gregg W Stone, et al.
Circulation|August 3, 2016
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)Matthew A Cavender, Deepak L Bhatt, Gregg W Stone, et al.
JAMA|November 20, 2013
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trialStephen J Nicholls, John J P Kastelein, Gregory G Schwartz, et al.
Circulation. Cardiovascular Interventions|December 17, 2021
Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIXMatthew A Cavender, Robert A Harrington, Gregg W Stone, et al.
Journal of the American College of Cardiology|May 6, 2021
Predicting In-Hospital Mortality in Patients Undergoing Percutaneous Coronary InterventionYulanka S Castro-Dominguez, Yongfei Wang, Karl E Minges, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 30, 2020
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney FoundationKatherine R Tuttle, Frank C Brosius, Matthew A Cavender, et al.
Pageof 9